Bambusa Therapeutics Reports Potentially Transformative Preliminary Proof-of-Concept Results for BBT001 in Atopic Dermatitis, Reinforcing Its Best-in-Disease Potential
BBT001 delivered highly statistically significant and clinically meaningful improvement in EASI beginning at Week 1, with responses continuing to improve over time Fast-onset and potent itch relief was observed as early as Day 1 after the first dose...